和迅生命科學股份有限公司 Approved
最後更新時間 2025/07/18 , 07:16 AM
最後更新時間 2025/07/18 , 07:16 AM
負責人
Huang,Ji-Hong
統一編號
50924393
成立日期
2019/06/12
資本額
NT$1,000,000,000
實收資本額
NT$460,000,000
股票代號
6986
電話
03-3175088
地址
6F, No. 1490, Chunrih Rd., Bianzhou Vil., Taoyuan Dist., Taoyuan City, 330, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Huang,Ji-Hong Chairman 4.57%
Wen,Zheng-Han Director 8.86%
Chen,Hong-Wen Director 0.00%
Chen,Ming-Xian Director 0.00%
Ceres Capital Co., Ltd. Director 3.41%
FU FENG SHENG INVESTMENT CO., LTD. Director 0.22%
Zhu,Jian-Cheng Independent Director 0.00%
Cai,Cai-Wei Independent Director 0.00%
Wei,Zong-De Independent Director 0.00%
營業項目
  • Wholesale of Pharmaceutical and Medical Goods(457113)
  • Retail Sale of Pharmaceutical and Medical Goods in Specialized Stores(475113)
  • Retail Sale of Pharmaceutical and Medical Goods in Specialized Stores(475199)
  • 公司歷程
  • Change Capital to 1,000,000,000
    2019/08/08
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2024 2023 2022
    Operating income 286,418 130,571 49,469
    Operating cost 25,747 16,838 4,859
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 260,671 113,733 44,610
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 260,671 113,733 44,610
    Operating expenses 104,940 86,359 53,587
    Other gain (loss), net - - -
    Operating profit (loss) 155,731 27,374 -8,977
    Non-operating income and expenses 5,738 6,115 3,789
    Net profit (loss) before tax 161,469 33,489 -5,188
    Income tax expense (benefits) 14,246 0 0
    Net profit (loss) of ongoing business for the current period 147,223 33,489 -5,188
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 147,223 33,489 -5,188
    Other comprehensive profit (loss), net - - -
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 147,223 33,489 -5,188
    Net profit (loss) attributable to owners of parent company - - -
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company - - -
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 3 0 0
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities - - -
    Net cash inflows (outflows) from investing activities - - -
    Net cash inflow (outflow) from financing activities - - -
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - - -
    Increase (decrease) in cash and cash equivalents in the current period - - -
    Beginning balance of cash and cash equivalents - - -
    Ending balance of cash and cash equivalents - - -
    項目 2024 2023 2022
    Current asset 483,246 363,672 211,243
    Non-current asset 223,673 207,757 192,909
    Total asset 706,919 571,429 404,152
    Current liability 53,755 30,170 20,028
    Non-current liability 32,584 67,902 69,256
    Total liability 86,339 98,072 89,284
    share capital 460,000 460,000 410,000
    Equity - secruity token - - -
    capital reserve 130,303 130,303 55,303
    retained earning 30,277 -116,946 -150,435
    Other equity - 0 -
    Treasury stock - - -
    Total equity attributable to owners of parent company - - -
    Equity attributable to former owner of business combination under common control - - 0
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 620,580 473,357 314,868
    Share capital awaiting retirement (unit: share) 0 - -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 13 10 7
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • StemPro II
  • 和迅
  • HEXUN
  • 和迅生命科學股份有限公司標章
  • HEXUN BIOSCIENCES
  • Hb4Cord
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。